Children Aged 12 - 18 Who Received COVID-19 Vaccines

Children aged 12-18 years who received the COVID-19 vaccine on May 11, 2022. The Food and Drug Administration (FDA) approved the COVOVAXTM vaccine for children and expanded the age coverage of the Moderna vaccine for COVID-19 prevention in children. The Protein-based COVOVAXTM vaccine is considered as an option for primary series vaccination in children aged 12 years and older, and in children who experienced severe side effects after receiving mRNA vaccines, such as myocarditis or severe allergies. COVOVAXTM is considered for children aged 12 years and older, administered as a primary series or booster dose. It has high safety, with side effects including local pain, fever, headache, and fatigue, which are mild and resolve within 1-2 days. The mRNA Moderna vaccine is considered for children aged 6-11 years at half the adult dose (50 micrograms or 0.25 ml), intramuscularly, in 2 doses spaced 8-12 weeks apart, to help reduce side effects related to myocarditis or pericarditis and to provide better immune stimulation.

Agency:

nakhonsawan-province

Licence:

License not specified

Category:

ข้อมูลสาธารณะ

Geographic coverage:

อำเภอ

Update frequency:

วัน

Years covered:

2020–2022

Source portal:

data_go_th

Updated:

25/08/2024

English title machine-translated from the Thai original

States daily, but the record has not been updated for 752 days (752 cycles)

The same record appears 2 more times on: gdcatalog, gdc_nakhonsawan — counted once here